摘要不同作用机制的口服降糖药联合治疗是临床管理2型糖尿病（T2DM）常用的降糖方案。早期联合治疗（起始联合或早期由单药治疗改为联合治疗）有助于新诊断T2DM患者缩短达标时间和延缓疾病进展。联合具有减重作用的降糖药可改善超重或肥胖合并T2DM患者的胰岛素抵抗，从而降低血糖控制的难度。联合具有心肾获益证据的降糖药还可实现远期的器官保护，改善临床结局。本共识为临床医生将各种口服降糖药联合治疗方案规范地应用于临床实践提供参考。

abstractsCombination therapies involving oral anti-diabetic agents with complementary mechanisms of action are widely employed in the clinical management of type 2 diabetes mellitus (T2DM). Initiating combination therapy early—either at diagnosis or through timely escalation from monotherapy—can expedite achievement of individualized glycemic targets and slow disease progression in newly diagnosed patients. The inclusion of agents with weight-reducing properties is particularly beneficial for overweight or obese individuals, as it enhances insulin sensitivity and facilitates glycemic control. Moreover, selecting combinations with proven cardiovascular and renal benefits offers long-term organ protection and improves overall prognosis. This consensus statement provides guidance on the optimal use of oral combination therapies for effective and individualized management of T2DM in clinical practice.